Combined with interferon and ribavirin, clinical trials on Vertex’s telaprevir demonstrate twice the success rate in clearing Hepatitis C in half the time as traditional combination therapy. While this alone is exciting, Vertex is exploring a range of drug combination options for battling the Hepatitis C virus.
Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C
Luke Timmerman 3/8/10
HIV has taught the pharmaceutical industry that the best way to fight an infectious virus that resists a single drug is to make a cocktail that attacks the virus in more than one way. Vertex Pharmaceuticals and its competitors are now following a similar formula with new therapies for hepatitis C.
Vertex, the Cambridge, MA-based company with operations in San Diego, offered a glimpse last week into its strategy for a two-drug combo that could significantly change hepatitis C treatment. If the company has mapped this out correctly, it could rid people of the virus while letting them ditch the detested standard therapies that force them to endure months of flu-like symptoms.
Continue reading this entire article:
http://www.xconomy.com/boston/2010/03/08/vertex-maps-out-combo-drug-as-new-game-plan-for-treating-hepatitis-c/